## Treatment of locally unresectable cancer of the stomach comparison of 5-fluorouracil alone with radiation plus of 5-fluorouracil--an Eastern Cooperative Oncology Group

Journal of Clinical Oncology 3, 373-378 DOI: 10.1200/jco.1985.3.3.373

**Citation Report** 

#	Article	IF	CITATIONS
1	Radiotherapy of gastric cancer with a three field combination: Feasibility, tolerance, and survival. International Journal of Radiation Oncology Biology Physics, 1987, 13, 1821-1827.	0.4	23
2	The role of radiation therapy in the control of pain from pancreatic carcinoma. Journal of Pain and Symptom Management, 1988, 3, 199-205.	0.6	40
3	What's New In General Surgery. Annals of Surgery, 1988, 208, 541-553.	2.1	165
4	Treatment of Probable Subclinical Liver Metastases and Gross Pancreatic Carcinoma with Hepatic Artery 5-Fluorouracil Infusion and Radiation Therapy. Acta Oncológica, 1988, 27, 377-381.	0.8	13
5	Combined Modality of Radiation and Chemotherapy for the Treatment of Gastric Carcinoma. Oncology Research and Treatment, 1989, 12, 156-160.	0.8	2
6	Overview of chemotherapy for pancreatic cancer. International Journal of Gastrointestinal Cancer, 1990, 7, 209-22.	0.4	48
7	Chemotherapy for pancreatic cancer. Bailliere's Clinical Gastroenterology, 1990, 4, 953-968.	0.9	32
8	Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The gastrointestinal tumor study group experience. Cancer, 1990, 65, 1478-1482.	2.0	41
9	Radiotherapy in the treatment of pancreatic cancer. Bailliere's Clinical Gastroenterology, 1990, 4, 969-983.	0.9	15
10	Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group Journal of Clinical Oncology, 1994, 12, 21-27.	0.8	83
11	Gastric Cancer: The role of radiation therapy in the management of gastric cancer. Annals of Oncology, 1994, 5, S37-S48.	0.6	14
12	Gastric Cancer: Preoperative chemotherapy of locally advanced gastric cancer. Annals of Oncology, 1994, 5, S59-S68.	0.6	42
13	Prospective phase I evaluation of radiation therapy, 5-fluorouracil, and levamisole in locally advanced gastrointestinal cancer. International Journal of Radiation Oncology Biology Physics, 1994, 28, 439-443.	0.4	1
14	Neoadjuvant chemotherapy in locally advanced gastric carcinoma—a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. European Journal of Cancer, 1994, 30, 1269-1275.	1.3	70
15	Role of Adjuvant Chemo- and Radiotherapy in Pancreatic Cancer. Digestive Surgery, 1994, 11, 408-413.	0.6	1
16	Adjuvant Therapy with Chemotherapy and Radiation Therapy in the Management of Carcinoma of the Pancreatic Head. Surgical Clinics of North America, 1995, 75, 925-938.	0.5	28
17	Adjuvant and systemic therapy for pancreatic cancer. Journal of Surgical Oncology, 1995, 11, 149-153.	1.4	1
18	Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: A phase II study from radiation therapy oncology group 85-04. Annals of Surgical Oncology, 1995, 2, 295-302.	0.7	29

#	Article	IF	Citations
19	Cisplatin and protracted venous infusion 5-fluorouracil (CF) — good symptom relief with low toxicity in advanced pancreatic carcinoma. Annals of Oncology, 1995, 6, 801-804.	0.6	38
20	Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas Journal of Clinical Oncology, 1995, 13, 2764-2768.	0.8	100
21	No standard treatment is available for advanced pancreatic cancer. European Journal of Cancer, 1995, 31, 882-887.	1.3	83
22	Long-Term Stabilization in a Patient with Nonresected Pancreatic Carcinoma Undergoing Chemotherapy. Oncology Research and Treatment, 1996, 19, 337-339.	0.8	1
23	Prognostic Factors in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. Pancreas, 1996, 12, 267-271.	0.5	43
24	Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Cancer, 1996, 78, 674-679.	2.0	17
25	Systemic and adjuvant therapy for patients with pancreatic carcinoma. Cancer, 1996, 78, 688-693.	2.0	11
26	Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. , 1996, 78, 674-679.		12
27	Systemic and adjuvant therapy for patients with pancreatic carcinoma. , 1996, 78, 688-693.		9
28	A phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma. International Journal of Radiation Oncology Biology Physics, 1996, 34, 445-450.	0.4	13
29	Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy. International Journal of Radiation Oncology Biology Physics, 1996, 35, 143-150.	0.4	21
30	A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. Investigational New Drugs, 1996, 14, 207-12.	1.2	6
31	Gastric cancer. Current Problems in Surgery, 1997, 34, 835-939.	0.6	40
33	Pancreatic adenocarcinoma: Adjuvant, neoadjuvant, and intraoperative chemoradiation. Seminars in Radiation Oncology, 1997, 7, 24-32.	1.0	0
34	Results of adjuvant therapy in resected pancreatic cancer. International Journal of Gastrointestinal Cancer, 1997, 21, 31-38.	0.4	9
35	Adjuvant chemotherapy in pancreatic cancer. International Journal of Gastrointestinal Cancer, 1997, 21, 59-63.	0.4	15
36	Patterns of failure and long-term results in high-risk resected gastric cancer treated with postoperative radiotherapy with or without intraoperative electron boost. , 1997, 66, 24-29.		27
37	Evolving trends in combined modality therapy for pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 227-234.	2.0	5

#	Article	IF	CITATIONS
38	Gesicherte und überlegenswerte Indikationen zur Strahlentherapie beim Magenkarzinom. Onkologe, 1998, 4, 324-331.	0.7	2
39	Review article: current treatment and optimal patient management in pancreatic cancer. Alimentary Pharmacology and Therapeutics, 1998, 12, 949-964.	1.9	25
41	Combined Radiochemotherapy with 5-Fluorouracil in Locally Advanced and Metastatic Pancreatic Carcinoma. Oncology Research and Treatment, 1998, 21, 420-424.	0.8	0
42	Pancreaticobiliary cancer: The future aspects of medical oncology. Annals of Oncology, 1999, 10, S296-S299.	0.6	11
43	Current chemotherapeutic possibilities in pancreaticobiliary cancer. Annals of Oncology, 1999, 10, S157-S161.	0.6	23
44	Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 1999, 45, 291-295.	0.4	35
46	Non-surgical treatments of pancreatic cancer. International Journal of Clinical Oncology, 1999, 4, 257-266.	1.0	14
48	Practical Recommendations for the Management of Adenocarcinoma of the Pancreas. Drugs, 1999, 57, 69-79.	4.9	13
49	Treatment of cancer of the exocrine pancreas. American Journal of Surgery, 1999, 177, 257-265.	0.9	34
50	Unresectable Adenocarcinoma of the Pancreas: Patterns of Failure and Treatment Results. Cancer Investigation, 2000, 18, 309-313.	0.6	12
51	Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound?guided fine-needle injection in patients with advanced pancreatic carcinoma. , 2000, 88, 1325-1335.		255
53	A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2000, 47, 939-944.	0.4	19
54	Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2000, 46, 109-118.	0.4	35
55	Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. British Journal of Cancer, 2000, 82, 98-103.	2.9	61
56	Treatment of Resectable and Locally Advanced Pancreatic Cancer. Cancer Control, 2000, 7, 428-436.	0.7	27
57	A multispecialty approach to the diagnosis and management of pancreatic cancer. American Journal of Gastroenterology, 2000, 95, 17-31.	0.2	148
58	Unresectable Adenocarcinoma of the Pancreas. Cancer Investigation, 2000, 18, 406-407.	0.6	0
59	Chemotherapy for upper gastrointestinal tumours. Postgraduate Medical Journal, 2000, 76, 321-321.	0.9	8

#	Article	IF	CITATIONS
61	THERAPY FOR REGIONALLY UNRESECTABLE PANCREATIC CANCER. Surgical Clinics of North America, 2001, 81, 691-697.	0.5	7
62	Pancreatic cancer: the evolving role of systemic therapy. Expert Opinion on Pharmacotherapy, 2001, 2, 1939-1947.	0.9	6
63	Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer 1 1Preliminary abstract submitted to the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 20–23, 2000 International Journal of Radiation Oncology Biology Physics, 2001, 51, 974-981.	0.4	24
64	Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas. Journal of Gastrointestinal Surgery, 2001, 5, 2-5.	0.9	20
65	Management of upper gastrointestinal cancers. Quality in Health Care: QHC, 2001, 10, 57-64.	1.2	1
66	Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors. Expert Review of Anticancer Therapy, 2001, 1, 258-268.	1.1	3
68	Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. British Journal of Cancer, 2002, 87, 497-501.	2.9	22
70	Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma with Combined Radiochemotherapy with 5-Fluorouracil and Cisplatin. Pancreas, 2002, 25, 360-365.	0.5	28
71	Update on pancreatic cancer. Current Opinion in Oncology, 2002, 14, 424-430.	1.1	30
72	Management of locally advanced adenocarcinoma of the pancreas. Hematology/Oncology Clinics of North America, 2002, 16, 95-103.	0.9	10
73	Current and future strategies for combined-modality therapy in pancreatic cancer. Current Oncology Reports, 2002, 4, 202-212.	1.8	8
74	Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Critical Reviews in Oncology/Hematology, 2002, 43, 57-62.	2.0	15
75	Multimodality Treatment Approaches in Pancreatic Cancer: Current Status and Future Perspectives. European Surgery - Acta Chirurgica Austriaca, 2002, 34, 42-57.	0.3	3
76	Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma. European Journal of Cancer Care, 2002, 11, 100-107.	0.7	11
77	Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. International Journal of Radiation Oncology Biology Physics, 2002, 53, 140-145.	0.4	41
78	Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 146-150.	0.4	149
79	Unresolved Issues in the Management of Locally Advanced Non-Metastatic Pancreas Cancer. Clinical Oncology, 2002, 14, 303-307.	0.6	0
81	Combined modality therapy for pancreatic cancer. Seminars in Oncology, 2003, 30, 71-79.	0.8	27

#	Article	IF	Citations
82	Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer, 2003, 97, 1346-1352.	2.0	29
83	Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. International Journal of Radiation Oncology Biology Physics, 2003, 57, 98-104.	0.4	197
84	Curative treatment of gastric cancer: towards a multidisciplinary approach?. Critical Reviews in Oncology/Hematology, 2003, 46, 59-100.	2.0	41
85	Should patients with locally advanced, non-metastatic carcinoma of the pancreas be irradiated?. Pancreatology, 2003, 3, 359-366.	0.5	14
86	The role of intraoperative radiotherapy in pancreatic cancer. Surgical Oncology Clinics of North America, 2003, 12, 965-977.	0.6	27
87	Intraoperative radiotherapy in the multimodality approach to gastric cancer. Surgical Oncology Clinics of North America, 2003, 12, 955-964.	0.6	8
89	Paclitaxel and Concurrent Radiation in Upper Gastrointestinal Cancers. Cancer Investigation, 2003, 21, 887-896.	0.6	22
90	Developments in the Systemic Therapy of Pancreatic Cancer. Cancer Investigation, 2003, 21, 73-86.	0.6	30
91	Treatment of Locally Advanced Pancreatic Cancer in the Real World: Population-Based Practices and Effectiveness. Journal of Clinical Oncology, 2003, 21, 3409-3414.	0.8	93
92	Adjuvant therapy in pancreatic cancer: historical and current perspectives. Annals of Oncology, 2003, 14, 675-692.	0.6	115
93	Surgical Resection After Preoperative Chemoradiotherapy Benefits Selected Patients With Unresectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 30-36.	0.6	78
95	The Treatment of Locally Advanced Pancreatic Cancer: A Practice Guideline. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 161-167.	1.8	13
96	Gastrointestinal Cancers. , 0, , 117-139.		0
98	Radiochemotherapy in Unresectable Pancreatic Cancer. , 2004, 38, 87-93.		1
101	Modern management of pancreatic carcinoma. Internal Medicine Journal, 2004, 34, 475-481.	0.5	38
102	Cancer and Leukemia Group B (CALGB) 89805: Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas. International Journal of Gastrointestinal Cancer, 2004, 34, 107-116.	0.4	88
104	A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1494-1501.	0.4	46
105	The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surgical Oncology Clinics of North America, 2004, 13, 711-735.	0.6	16

#	Article	IF	CITATIONS
106	Adjuvant therapy for pancreatic cancer: an evolving paradigm. Surgical Oncology Clinics of North America, 2004, 13, 605-620.	0.6	4
107	The evolving role of postoperative adjuvant radiation therapy for pancreatic cancer. Surgical Oncology Clinics of North America, 2004, 13, 589-604.	0.6	2
108	Emerging drugs in pancreatic cancer. Expert Opinion on Emerging Drugs, 2004, 9, 73-89.	1.0	2
109	A Phase II Study of Alternating Cycles of Split Course Radiation Therapy and Gemcitabine Chemotherapy for Inoperable Pancreatic or Biliary Tract Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 234-241.	0.6	24
110	Phase II Trial of Induction Gemcitabine/CPT-11 Followed by a Twice-Weekly Infusion of Gemcitabine and Concurrent External Beam Radiation for the Treatment of Locally Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 345-350.	0.6	41
111	A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1345-1350.	0.4	138
112	Gastric cancer. Critical Reviews in Oncology/Hematology, 2005, 54, 209-241.	2.0	73
113	Docetaxel in the Management of Advanced Pancreatic Cancer. Seminars in Oncology, 2005, 32, 10-23.	0.8	11
114	Radiochemotherapy in the Management of Pancreatic Cancer—Part II: Use in Adjuvant and Locally Unresectable Settings. Seminars in Radiation Oncology, 2005, 15, 235-244.	1.0	9
115	Systemic Therapy for Pancreatic Cancer. Seminars in Radiation Oncology, 2005, 15, 245-253.	1.0	8
116	Multimodality Approaches for Pancreatic Cancer. Ca-A Cancer Journal for Clinicians, 2005, 55, 352-367.	157.7	28
117	Chemotherapy prolongs survival in inoperable pancreatic carcinoma. British Journal of Surgery, 2005, 81, 882-885.	0.1	229
118	Treatment of Metastatic Pancreatic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 627-636.	2.3	16
119	Locally Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2005, 23, 4538-4544.	0.8	196
120	Current management of locally advanced pancreatic cancer. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 356-364.	1.7	20
121	Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut, 2005, 54, v1-v16.	6.1	207
122	Locally Advanced Pancreatic Cancer Treated with Radiation and 5-Fluorouracil: A First Step to Neoadjuvant Treatment?. Digestive Surgery, 2005, 22, 191-197.	0.6	10
123	Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer. Current Cancer Therapy Reviews, 2005, 1, 227-237.	0.2	3

#	Article	IF	CITATIONS
124	Treatment for Pancreatic Cancer: Current Therapy and Continued Progress. Gastroenterology, 2005, 128, 1642-1654.	0.6	142
125	Pancreatic Cancer: Basic and Clinical Aspects. Gastroenterology, 2005, 128, 1606-1625.	0.6	279
126	Treatment update for metastatic pancreatic cancer. Community Oncology, 2006, 3, 428-430.	0.2	0
127	Radiation Therapy for Gastrointestinal Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 287-320.	0.9	8
128	The Effect of Radiation Therapy on Normal Tissue Function. Hematology/Oncology Clinics of North America, 2006, 20, 141-163.	0.9	20
129	Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. , 2006, , CD002093.		102
130	Phase II Study of Induction Chemotherapy with Gemcitabine plus 5-Fluorouracil Followed by Gemcitabine-Based Concurrent Chemoradiotherapy for Unresectable Locally Advanced Pancreatic Cancer. Tumori, 2006, 92, 481-486.	0.6	14
131	Gemcitabine Chemotherapy Versus 5-fluorouracil-based Concurrent Chemoradiotherapy in Locally Advanced Unresectable Pancreatic Cancer. Pancreas, 2006, 33, 397-402.	0.5	32
132	Current therapies and advances in the treatment of pancreatic cancer. Critical Reviews in Oncology/Hematology, 2006, 58, 231-241.	2.0	85
133	Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival. Annals of Surgical Oncology, 2006, 13, 1201-1208.	0.7	130
134	Cancer of the pancreas. Gastroenterologie Clinique Et Biologique, 2006, 30, 75-80.	0.9	1
135	Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 2006, 107, 2589-2596.	2.0	76
136	Cancer du pancréas exocrine. , 2006, , 159-178.		0
137	Locally Advanced Pancreatic Cancer: Current Therapeutic Approach. Oncologist, 2006, 11, 612-623.	1.9	89
139	Phase II Trial of Infusional Fluorouracil, Leucovorin, Mitomycin, and Dipyridamole in Locally Advanced Unresectable Pancreatic Adenocarcinoma: SWOG S9700. Journal of Clinical Oncology, 2007, 25, 1665-1669.	0.8	37
140	Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. British Journal of Cancer, 2007, 96, 1353-1357.	2.9	16
142	Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies. Journal of Clinical Oncology, 2007, 25, 326-331.	0.8	485
143	Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Medical Physics, 2007, 34, 521-529.	1.6	46

#	Article	IF	CITATIONS
144	Pancreatic cancer: From pathogenesis to cure. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 997-1014.	1.0	11
145	The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 385-388.	0.4	87
146	Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1027-1036.	0.4	41
147	Full-Dose Gemcitabine and Concurrent Radiotherapy for Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 801-808.	0.4	203
148	A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 809-816.	0.4	104
149	Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. British Journal of Cancer, 2007, 96, 1183-1190.	2.9	212
150	Rolling review: gastrointestinal malignancy. Alimentary Pharmacology and Therapeutics, 1993, 7, 661-677.	1.9	2
151	Future Chemoradiation Strategies in Pancreatic Cancer. Seminars in Oncology, 2007, 34, 335-346.	0.8	33
152	Locally Advanced Pancreatic Cancer: A Review. Seminars in Oncology, 2007, 34, 327-334.	0.8	31
153	Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?. Gastroenterologie Clinique Et Biologique, 2007, 31, 151-156.	0.9	6
154	Predicting Unresectability in Pancreatic Cancer Patients: The Additive Effects of CT and Endoscopic Ultrasound. Journal of Gastrointestinal Surgery, 2007, 11, 36-42.	0.9	25
155	Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemotherapy and Pharmacology, 2008, 62, 647-653.	1.1	20
156	Radiotherapy in Pancreatic Cancer. Strahlentherapie Und Onkologie, 2008, 184, 557-564.	1.0	14
158	Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan. International Journal of Clinical Oncology, 2008, 13, 127-131.	1.0	6
159	Chemoradiotherapy for unresectable pancreatic cancer. International Journal of Clinical Oncology, 2008, 13, 121-126.	1.0	28
160	Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer. Journal of Gastroenterology, 2008, 43, 875-880.	2.3	1
161	Neoadjuvant treatment for pancreatic cancer—A review. Critical Reviews in Oncology/Hematology, 2008, 65, 263-274.	2.0	24
162	Pancreatic cancer: Progress in cancer therapy. Critical Reviews in Oncology/Hematology, 2008, 67, 27-38.	2.0	32

ARTICLE IF CITATIONS Multicriteria Optimization in Intensity-Modulated Radiation Therapy Treatment Planning for Locally Advanced Cancer of the Pancreatic Head. International Journal of Radiation Oncology Biology 163 0.4 66 Physics, 2008, 72, 1208-1214. Chemoradiotherapy for Locally Advanced Pancreatic Cancer: a Radiotherapy Dose Escalation and 164 0.6 Organ Motion Study. Clinical Oncology, 2008, 20, 541-547. Pancreatic Cancer within a UK Cancer Network with Special Emphasis on Locally Advanced 165 0.6 19 Non-metastatic Pancreatic Cancer. Clinical Oncology, 2008, 20, 535-540. Tumor-Node-Metastasis Staging of Pancreatic Adenocarcinoma. Ca-A Cancer Journal for Clinicians, 103 2008, 58, 111-125. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic 167 3.5 41 carcinoma. Journal of Experimental and Clinical Cancer Research, 2008, 27, 41. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 0.6 advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Annals of Oncology, 2008, 19, 1592-1599 Concomitant Administration of Weekly Oxaliplatin, Fluorouracil Continuous Infusion, and Radiotherapy After 2 Months of Gemcitabine and Oxaliplatin Induction in Patients With Locally 170 0.8 55 Advanced Pancreatic Cancer: A Groupe Coordinateur Multidisciplinaire en Oncologie Phase II Study. Journal of Clinical Oncology, 2008, 26, 1080-1085. Multidisciplinary management of resectable adenocarcinoma of the pancreatic head. Expert Review of 171 1.1 Anticancer Therapy, 2008, 8, 1611-1621. Upper gastrointestinal tumors: current status and future perspectives. Expert Review of Anticancer 172 1.1 6 Therapy, 2008, 8, 975-991. Pancreatic cancerâ€"is the wall crumbling?. Annals of Oncology, 2008, 19, 1224-1230. Is there a role for advanced radiation therapy technologies in the treatment of pancreatic 174 0 1.1 adenocarcinoma?. Future Oncology, 2008, 4, 241-255. New directions in the management of advanced pancreatic cancer: a review. Anti-Cancer Drugs, 2008, 19, 435-446. 176 TREATMENT STRATEGY FOR LOCALLY ADVANCED PANCREATIC CANCER. Pancreas, 2008, 37, 112. 0.5 0 Treatment of locally advanced and metastatic pancreatic cancer., 0, , 166-174. Radiation Therapy for Gastric Cancer Bleeding. Tumori, 2009, 95, 726-730. 178 42 0.6 Emerging drugs in the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2009, 14, 311-328. 179 1.0 Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative 180 0.8 221 Systematic Review. Journal of Clinical Oncology, 2009, 27, 2269-2277. Chemoradiotherapy in pancreatic carcinoma. Indian Journal of Medical and Paediatric Oncology, 2009, 181 0.1 30, 55-60.

#	Article	IF	CITATIONS
182	Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer, 2009, 115, 665-672.	2.0	353
183	Stereotactic radiotherapy for pancreatic cancer?. Cancer, 2009, 115, 468-472.	2.0	8
184	Clinical impact of radiotherapy for locally advanced pancreatic cancer. Journal of Gastroenterology, 2009, 44, 1209-1214.	2.3	10
185	Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 535-541.	1.1	27
186	Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2009, 64, 1253-1259.	1.1	32
187	Efficacy and Factors Affecting Outcome of Gemcitabine Concurrent Chemoradiotherapy in Patients With Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 73, 159-165.	0.4	21
188	Gastric cancer. Critical Reviews in Oncology/Hematology, 2009, 71, 127-164.	2.0	347
189	The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2009, 13, 123-143.	0.6	14
191	Surgical Treatment of Pancreatic Diseases. , 2009, , .		5
192	Survival after radiotherapy in gastric cancer: Systematic review and meta-analysis. Radiotherapy and Oncology, 2009, 92, 176-183.	0.3	84
193	Gastric cancer. Lancet, The, 2009, 374, 477-490.	6.3	871
195	Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. The Cochrane Library, 2009, , CD002093.	1.5	24
196	An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. Anti-Cancer Drugs, 2010, 21, 459-464.	0.7	8
197	EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract. Current Protein and Peptide Science, 2010, 11, 436-450.	0.7	11
198	Pancreatic Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 972-1017.	2.3	152
199	External Beam Radiotherapy Plus 24-Hour Continuous Infusion of Gemcitabine in Unresectable Pancreatic Carcinoma: Long-Term Results of a Phase II Study. International Journal of Radiation Oncology Biology Physics, 2010, 76, 831-838.	0.4	18
200	Phase I Study of Daily Irinotecan as a Radiation Sensitizer for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 409-413.	0.4	2
201	Patterns of Radiotherapy Practice for Pancreatic Cancer in Japan: Results of the Japanese Radiation Oncology Study Group (JROSG) Survey. International Journal of Radiation Oncology Biology Physics, 2010, 77, 743-750.	0.4	7

	CHATION REF	OKI	
ARTICLE Estimating Optimal Dose of Twice-Weekly Gemcitabine for Concurrent Chemoradiotherapy in Unresectable Pancreatic Carcinoma: Mature Results of GEMRT-01 Phase I Trial. International Jourr Radiation Oncology Biology Physics, 2010, 77, 1426-1432.	nal of	IF 0.4	CITATIONS
Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results First 85 Patients. Journal of Gastrointestinal Surgery, 2010, 14, 1547-1559.	s of	0.9	103
Stereotactic Body Radiotherapy: A Review. Clinical Oncology, 2010, 22, 157-172.		0.6	128
Efficacy and Tolerability of Limited Field Radiotherapy with Concurrent Capecitabine in Locally Advanced Pancreatic Cancer. Clinical Oncology, 2010, 22, 570-577.		0.6	15
Outcomes and Tolerability of Chemoradiation Therapy for Pancreatic Cancer Patients Aged 75 Ye Older. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1171-1177.	ars or	0.4	34
Stereotactic Body Radiotherapy and Gemcitabine for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 735-742.		0.4	215
The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiation Oncology, 2 5, 64.	010,	1.2	44
The Locally Advanced Nonmetastatic Cancer. Medical Radiology, 2010, , 123-136.		0.0	0
Radiation Therapy in Operable and Locally Advanced Pancreatic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1022-1031.		2.3	6
Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506. Japanese Journal of Clinical Oncology, 2010, 40, 573-579.		0.6	63
The Glasgow Prognostic Score Is a Good Predictor of Treatment Outcome in Patients with Unresectable Pancreatic Cancer. Chemotherapy, 2010, 56, 501-506.		0.8	48
Chemoradiation in Pancreatic Adenocarcinoma: A Literature Review. Oncologist, 2010, 15, 259-2	69.	1.9	25
The role of radiotherapy in locally advanced pancreatic carcinoma. Nature Reviews Gastroenterolo and Hepatology, 2010, 7, 437-447.	ogy	8.2	36
Phase I Trial of Gemcitabine Dose Escalation with Concurrent Radiotherapy for Patients with Loca Advanced Pancreatic Cancer. Pancreatology, 2010, 10, 60-65.	lly	0.5	1
Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinica Oncology, 2010, 7, 163-172.	1	12.5	704
Pancreatic cancer: Progress made. Acta Oncológica, 2010, 49, 407-417.		0.8	29

Principles of Anticancer Drug Development., 2011,,.

## 220 Gastrointestinal Oncology. , 2011, , .

#

#	Article	IF	CITATIONS
222	Induction Chemotherapy With Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by Concomitant Chemoradiotherapy in Patients With Locally Advanced Pancreatic Cancer: A Taiwan Cooperative Oncology Group Phase II Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, e749-e757.	0.4	20
223	Pretreatment Carbohydrate Antigen 19-9 Level Indicates Tumor Response, Early Distant Metastasis, Overall Survival, and Therapeutic Selection in Localized and Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e623-e630.	0.4	19
224	Induction Gemcitabine and Stereotactic Body Radiotherapy for Locally Advanced Nonmetastatic Pancreas Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e615-e622.	0.4	207
225	Randomized trials in exocrine pancreatic cancer. Przeglad Gastroenterologiczny, 2011, 2, 85-96.	0.3	1
226	Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. Oncology Letters, 2011, 2, 195-200.	0.8	1
227	Phase II Study of Radiation Therapy Combined With Weekly Low-Dose Gemcitabine for Locally Advanced, Unresectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 115-119.	0.6	32
228	Stereotactic Body Radiotherapy in the Treatment of Advanced Adenocarcinoma of the Pancreas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 63-69.	0.6	148
229	A Phase II Study of Gemcitabine in Combination With Radiation Therapy in Patients With Localized, Unresectable, Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 460-465.	0.6	60
231	Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas. Cancer Chemotherapy and Pharmacology, 2011, 67, 621-627.	1.1	5
232	Current Treatment Options for Pancreatic Carcinoma. Current Oncology Reports, 2011, 13, 195-205.	1.8	33
233	Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterology, 2011, 11, 123.	0.8	56
234	A phase 2 trial of gemcitabine, 5â€fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma. Cancer, 2011, 117, 2620-2628.	2.0	24
235	Positional Reproducibility of Pancreatic Tumors Under End-Exhalation Breath-Hold Conditions Using a Visual Feedback Technique. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1565-1571.	0.4	50
236	Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Expert Review of Anticancer Therapy, 2011, 11, 1555-1565.	1.1	13
237	Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 2011, 29, 4105-4112.	0.8	721
238	Locally Advanced Pancreatic Cancer: Where Should We Go From Here?. Journal of Clinical Oncology, 2011, 29, 4066-4068.	0.8	30
239	Treatment of resectable gastric cancer. Therapeutic Advances in Gastroenterology, 2012, 5, 49-69.	1.4	70
240	Combined modality treatments in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S71-S81.	1.5	10

#	Article	IF	CITATIONS
241	The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 2012, 106, 61-69.	2.9	14
242	Feasibility of Electromagnetic Transponder Use to Monitor Inter- and Intrafractional Motion in Locally Advanced Pancreatic Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2012, 83, 566-573.	0.4	22
243	Treatment of Locally Advanced Pancreatic Cancer: The Role of Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 508-518.	0.4	36
244	Radiotherapy Technical Considerations in the Management of Locally Advanced Pancreatic Cancer: American-French Consensus Recommendations. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1355-1364.	0.4	63
245	Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Practical Radiation Oncology, 2012, 2, 77-85.	1.1	28
246	Impact of omission of elective nodal irradiation on treatment outcomes in locally advanced pancreatic adenocarcinoma patients treated with definitive concurrent chemoradiotherapy. Pancreatology, 2012, 12, 434-439.	0.5	2
247	Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). Gastroenterology Clinics of North America, 2012, 41, 189-209.	1.0	31
248	EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointestinal Endoscopy, 2012, 75, 332-338.	0.5	138
249	Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery, 2012, 152, 851-862.	1.0	97
250	Impact of Age and Comorbidities on the Treatment of Gastrointestinal Malignancies. Seminars in Radiation Oncology, 2012, 22, 311-320.	1.0	11
251	Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 381-389.	1.1	22
253	The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer. Radiation Oncology, 2012, 7, 203.	1.2	10
254	Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiation Oncology, 2012, 7, 37.	1.2	34
255	Prospective Phase I Study of Capecitabine and Oxaliplatin Concurrent with Radiation Therapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma, and Retrospective Comparison to Concurrent 5-Fluorouracil/Radiation and Gemcitabine/Radiation. Journal of Gastrointestinal Cancer, 2012. 43. 258-266.	0.6	0
256	Randomized trials and quality assurance in gastric cancer surgery. Journal of Surgical Oncology, 2013, 107, 298-305.	0.8	8
257	Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiation Oncology, 2013, 8, 44.	1.2	104
258	Identification of Distinct Phenotypes of Locally Advanced Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 2013, 44, 73-78.	0.6	1
259	Multidisciplinary Management ofÂPancreatic Cancer. Surgical Oncology Clinics of North America, 2013, 22, 265-287.	0.6	29

		CITATION RE	PORT	
#	Article		IF	CITATIONS
260	Gastric Cancer: Current Status of Diagnosis and Treatment. Cancers, 2013, 5, 48-63.		1.7	159
262	Stereotactic body radiotherapy in the treatment of Pancreatic Adenocarcinoma in elder Radiation Oncology, 2013, 8, 240.	ly patients.	1.2	50
263	Chemoradiation Therapy. Surgical Oncology Clinics of North America, 2013, 22, 511-52	24.	0.6	13
264	Current concepts and novel targets in advanced pancreatic cancer. Gut, 2013, 62, 317-	326.	6.1	134
265	Advanced-stage pancreatic cancer: therapy options. Nature Reviews Clinical Oncology,	2013, 10, 323-333.	12.5	183
266	Irreversible Electroporation in Locally Advanced Pancreatic Cancer: Potential Improved G Survival. Annals of Surgical Oncology, 2013, 20, 443-449.	Dverall	0.7	258
267	Performance status of patients is the major prognostic factor at all stages of pancreatic International Journal of Clinical Oncology, 2013, 18, 839-846.	: cancer.	1.0	94
268	Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil a Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results. Journal of Clinical C 2013, 31, 886-894.	nd vncology,	0.8	173
269	The Controversial Role of Chemoradiation for Patients With Locally Advanced Pancreati Oncologist, 2013, 18, 981-985.	c Cancer.	1.9	4
270	Gastric cancer: past accomplishments, present approaches and future aspirations. Clini (London, England), 2013, 10, 47-77.	cal Practice	0.1	0
271	Effects of interportal error on dose distribution in patients undergoing breathâ€holding intensityâ€modulated radiotherapy for pancreatic cancer: evaluation of a new treatmer method. Journal of Applied Clinical Medical Physics, 2013, 14, 43-51.	it planning	0.8	2
272	FDG-PET/CT-based restaging may alter initial management decisions and clinical outcon with locally advanced pancreatic carcinoma planned to undergo chemoradiotherapy. Ca 2013, 13, 423-428.		1.2	18
273	Radiation Therapy Improves Survival Outcome in Pancreatic Adenocarcinoma: Comparis Institutional Experience at the University of Nebraska Medical Center with SEER Data. Jo Radiotherapy, 2014, 2014, 1-6.		0.2	0
274	Prognostic Significance of Volume-Based FDG PET/CT Parameters in Patients with Local Pancreatic Cancer Treated with Chemoradiation Therapy. Yonsei Medical Journal, 2014,		0.9	32
275	Management of borderline and locally advanced pancreatic cancer: Where do we stand Journal of Gastroenterology, 2014, 20, 2255.	?. World	1.4	76
276	Clinical Outcome of Palliative Radiotherapy for Locally Advanced Symptomatic Gastric ( Modern Era. Medicine (United States), 2014, 93, e118.	Cancer in the	0.4	62
277	18F-fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with cancer. Nuclear Medicine Communications, 2014, 35, 1112-1118.	n pancreatic	0.5	14
278	Multimodal Therapies for Pancreatic Cancer. , 2014, , 39-73.			0

#	ARTICLE	IF	Citations
279	Locally Advanced Pancreatic Cancer: The Role of Definitive Chemoradiotherapy. Clinical Oncology, 2014, 26, 560-568.	0.6	42
280	Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 205-210.	1.1	12
281	Management Options in Locally Advanced Pancreatic Cancer. Current Oncology Reports, 2014, 16, 388.	1.8	29
282	TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clinical and Translational Oncology, 2014, 16, 865-878.	1.2	5
283	Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial. Digestive and Liver Disease, 2014, 46, 950-955.	0.4	5
284	Consolidating duodenal and small bowel toxicity data via isoeffective dose calculations based on compiled clinical data. Practical Radiation Oncology, 2014, 4, e125-e131.	1.1	10
285	Performance of a Nomogram Predicting Disease-Specific Survival After an RO Resection for Gastric Cancer in Patients Receiving Postoperative Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 88, 624-629.	0.4	13
286	Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma. Oncology Letters, 2014, 8, 1302-1306.	0.8	6
287	Pancreatic Adenocarcinoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1083-1093.	2.3	307
288	Evolving Treatment Options for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 167-172.	2.3	4
289	Potential risk of residual cancer cells in the surgical treatment of initially unresectable pancreatic carcinoma after chemoradiotherapy. World Journal of Surgical Oncology, 2015, 13, 209.	0.8	1
290	The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 259-265.	0.6	171
291	Structure of the Varicella Zoster Virus Thymidylate Synthase Establishes Functional and Structural Similarities as the Human Enzyme and Potentiates Itself as a Target of Brivudine. PLoS ONE, 2015, 10, e0143947.	1.1	16
292	Pancreatic Adenocarcinoma. , 2015, , 283-313.		3
294	Current Adjuvant Therapeutic Approaches for Pancreatic Cancer. Advances in Therapy, 2015, 32, 42-56.	1.3	6
295	Advances in Chemotherapy for Pancreatic Cancer. Indian Journal of Surgical Oncology, 2015, 6, 47-56.	0.3	5
296	Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 741-759.	0.9	9
297	A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2015, 46, 284-290.	0.6	14

#	Article	IF	CITATIONS
298	Approach to Patients With Pancreatic Cancer Without Detectable Metastases. Journal of Clinical Oncology, 2015, 33, 1770-1778.	0.8	117
299	Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis. Radiation Oncology, 2015, 10, 14.	1.2	26
300	Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiology and Oncology, 2015, 49, 147-154.	0.6	50
301	Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. Journal of Oncology Practice, 2016, 12, 915-923.	2.5	19
302	Role of Radiotherapy in Locally Advanced Pancreatic Cancer. , 2016, , 1-26.		0
303	Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer. Journal of Radiation Research, 2016, 57, i53-i57.	0.8	68
304	Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience. Journal of Gastrointestinal Cancer, 2016, 47, 196-201.	0.6	5
305	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA - Journal of the American Medical Association, 2016, 315, 1844.	3.8	801
306	Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. Seminars in Radiation Oncology, 2016, 26, 320-337.	1.0	21
308	Particle Radiation Therapy for Gastrointestinal Cancers. Current Oncology Reports, 2016, 18, 17.	1.8	11
309	Meta-analyses of treatment standards for pancreatic cancer. Molecular and Clinical Oncology, 2016, 4, 315-325.	0.4	31
311	Current standards and new innovative approaches for treatment of pancreatic cancer. European Journal of Cancer, 2016, 57, 10-22.	1.3	138
312	Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology, 2016, 150, 1659-1672.e5.	0.6	139
313	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Oncologist, 2016, 21, 178-187.	1.9	47
314	Stereotactic Body Radiation Therapy as an Emerging Option for Localized Pancreatic Cancer. , 2016, , 125-141.		1
315	Radiation Therapy for Pancreatic Cancer. , 2016, , 237-249.		1
316	Pancreatic Masses. , 2016, , .		0
318	Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 517-522.	0.6	4

ARTICLE IF CITATIONS Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic 319 0.6 59 Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 152-157. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochimica Et 3.3 Biophysica Acta: Reviews on Cancer, 2017, 1868, 69-92. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does 323 the Nature of Chemotherapy Regimen Influence Outcomes?. Annals of Surgical Oncology, 2017, 24, 0.7 45 1406-1413. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival 324 2.0 in locally advanced pancreatic cancer. Cancer, 2017, 123, 3816-3824. Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced 325 1.0 12 unresectable pancreatic cancer. British Journal of Radiology, 2017, 90, 20170165. Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Advances in Radiation Oncology, 2017, 2, 27-36. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer 327 0.5 12 Database. Pancreas, 2017, 46, 904-912. Randomized Clinical Trials in Pancreatic Cancer. Surgical Oncology Clinics of North America, 2017, 26, 328 0.6 767-790. Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable 329 2 0.7 pancreatic adenocarcinoma. Journal of Radiation Oncology, 2017, 6, 279-286. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. Pancreatology, 2017, 17, 833-838. 331 Ablative Radiotherapy Doses for Locally Advanced. Cancer Journal (Sudbury, Mass), 2017, 23, 350-354. 1.0 14 Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. International Journal of Radiation Oncology Biology Physics, 2017, 97, 0.4 134 313-322. Palliative Radiation Oncology for Gastrointestinal Tract Malignancies., 2017,, 231-256. 333 0 Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS ONE, 2017, 12, e0186341. 334 1.1 Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for 335 0.4 28 borderline resectable pancreatic cancer. Annals of Surgical Treatment and Research, 2017, 93, 186. Gastrointestinal Cancer: Pancreas. Medical Radiology, 2017, , 211-227. 336 Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancerâ€"patterns of 337 0.6 18 care and overall survival. Journal of Gastrointestinal Oncology, 2017, 8, 766-777. Nonmetastatic pancreatic cancer. Strahlentherapie Und Onkologie, 2018, 194, 627-637.

#	Article	IF	CITATIONS
339	Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 815-821.	1.1	21
341	The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Irish Journal of Medical Science, 2018, 187, 887-894.	0.8	0
342	Chemotherapy and radiotherapy for advanced pancreatic cancer. The Cochrane Library, 2018, 2018, CD011044.	1.5	80
343	Role of Radiotherapy in Locally Advanced Pancreatic Cancer. , 2018, , 1435-1460.		0
344	Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 236-241.	0.6	15
345	The Evolving Role of Radiation in Pancreatic Cancer. Surgical Clinics of North America, 2018, 98, 113-125.	0.5	21
346	Locally advanced pancreatic cancer: An emerging entity. Current Problems in Cancer, 2018, 42, 12-25.	1.0	13
347	Atlas of PET-CT. , 2018, , .		0
348	Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. Journal of Gastrointestinal Oncology, 2018, 9, 982-988.	0.6	7
349	Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 1027-1036.	0.6	8
350	Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbeck's Archives of Surgery, 2018, 403, 917-932.	0.8	67
351	Currently available first-line drug therapies for treating pancreatic cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1927-1940.	0.9	5
352	Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer. Medicine (United States), 2018, 97, e12260.	0.4	6
353	The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. Cancer Research and Treatment, 2018, 50, 562-574.	1.3	16
354	Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer. Cancer Medicine, 2018, 7, 2913-2924.	1.3	16
355	Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Advances in Radiation Oncology, 2018, 3, 314-321.	0.6	20
356	Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer. Pancreatology, 2018, 18, 624-629.	0.5	4
357	Chemoradiotherapy versus chemotherapy for locally advanced unresectable pancreatic cancer: A systematic review and metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 392-401.	0.7	9

ARTICLE IF CITATIONS Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. 358 1.2 29 Radiation Oncology, 2018, 13, 118. Intensity-modulated radiotherapy with systemic chemotherapy improves survival in patients with nonmetastatic unresectable pancreatic adenocarcinoma: A propensity score-matched, nationwide, 0.3 19 population-based cohort study. Radiotherapy and Oncology, 2018, 129, 326-332. The Herb–Drug Pharmacokinetic Interaction of 5-Fluorouracil and Its Metabolite 5-Fluoro-5,6-Dihydrouracil with a Traditional Chinese Medicine in Rats. International Journal of 360 1.8 12 Molecular Sciences, 2018, 19, 25. Clinical Impact of Local Progression in Pancreatic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 711-717. Charged Particle Stereotactic Body Radiation Therapy., 2019, , 217-233. 363 0 Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy. Cancer Management and 364 Research, 2019, Volume 11, 8807-8815. Capecitabine for the treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 365 0.9 26 399-409. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Radiation 1.2 366 118 Oncology, 2019, 14, 95 Stereotactic body radiation therapy for locally advanced pancreatic cancer. PLoS ONE, 2019, 14, 367 1.1 45 e0214970. Palliative radiotherapy in symptomatic locally advanced gastric cancer: A phase <scp>II</scp> trial. 1.3 Cancer Medicine, 2019, 8, 1447-1458. Changing paradigm of radiation therapy for the treatment of pancreatic cancer. Precision Radiation 369 0 0.4 Oncology, 2019, 3, 149-162. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. 64 Annals of Surgical Óncology, 2019, 26, 109-117. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer. Journal of Cancer 371 1.2 9 Research and Clinical Oncology, 2020, 146, 417-428. Influence of dose-averaged linear energy transfer on tumour control after carbon-ion radiation therapy for pancreatic cancer. Clinical and Translational Radiation Oncology, 2020, 21, 19-24. Utilization of chemoradiation therapy provides strongest protective effect for avoidance of 373 postoperative pancreatic fistula following pancreaticoduodenectomy: A NSQIP analysis. Journal of 0.8 5 Surgical Oncology, 2020, 122, 1604-1611. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new 374 1.4 standard?. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093609. Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the 375 1.6 112Radioresistance of Pancreatic Cancer. Cancer Immunology Research, 2020, 8, 1440-1451. Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally 376 Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar. Frontiers in Oncology, 2020, 10, 1.3 600940.

#	Article	IF	CITATIONS
377	Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer. Radiation Oncology, 2020, 15, 101.	1.2	3
378	Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. Current Problems in Cancer, 2020, 44, 100607.	1.0	17
379	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas, 2020, 49, 822-829.	0.5	2
380	Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancerÂ(CRiSP): An international systematic review and metaâ€analysis. Cancer, 2020, 126, 2120-2131.	2.0	72
381	Efficacy and feasibility of re-irradiation using carbon ions for pancreatic cancer that recurs after carbon-ion radiotherapy. Clinical and Translational Radiation Oncology, 2021, 26, 24-29.	0.9	7
382	Concurrent high-dose intensity-modulated radiotherapy and chemotherapy for unresectable locally advanced and metastatic pancreatic cancer: a pilot study. Journal of Radiotherapy in Practice, 0, , 1-6.	0.2	0
383	Radiotherapy for locally advanced pancreatic ductal adenocarcinoma. Seminars in Oncology, 2021, 48, 106-110.	0.8	9
384	The Landmark Series: Locally Advanced Pancreatic Cancer and Ablative Therapy Options. Annals of Surgical Oncology, 2021, 28, 4173-4180.	0.7	8
385	Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy?. Radiation Oncology, 2021, 16, 53.	1.2	6
386	Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clinical and Translational Radiation Oncology, 2021, 27, 147-151.	0.9	0
387	Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 662205.	1.3	7
388	Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer—Ready for Prime Time?. JAMA Oncology, 2021, 7, 687.	3.4	4
389	Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1003-1012.	0.4	21
390	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Annals of Surgery, 2021, 274, 894-901.	2.1	15
391	Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era. American Surgeon, 2021, 87, 1386-1395.	0.4	3
392	The role of radiotherapy in locally advanced pancreatic cancer. British Journal of Radiology, 2021, 94, 20210044.	1.0	2
393	Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreatic cancer. Pancreatology, 2021, 21, 1052-1058.	0.5	2
394	Simulated dose painting of hypoxic sub-volumes in pancreatic cancer stereotactic body radiotherapy. Physics in Medicine and Biology, 2021, 66, 185008.	1.6	7

#	Article	IF	CITATIONS
395	Preoperative (Neoadjuvant) Therapy for Resectable Adenocarcinoma of the Pancreas. , 2002, , 243-254.		2
396	Introduction to Stereotactic Body Radiotherapy. , 2015, , 1-18.		2
398	Gastric IORT With or Without EBRT. , 1999, , 175-200.		2
399	Primary Advanced Unresectable Pancreatic Cancer. , 2008, 177, 79-93.		35
400	Can Adjuvant Chemoradiotherapy Replace Extended Lymph Node Dissection in Gastric Cancer?. Recent Results in Cancer Research, 2012, 196, 229-240.	1.8	6
401	Chemotherapy for Patients with Adenocarcinoma of the Pancreas. Recent Results in Cancer Research, 1996, 142, 415-424.	1.8	6
402	Treatment of Pancreatic Carcinoma: Therapeutic Nihilism?. Recent Results in Cancer Research, 1988, 110, 87-94.	1.8	4
403	Chemotherapy and radiotherapy for pancreatic and periampullary cancer. , 2012, , 972-978.e2.		1
404	Upper Gastrointestinal Malignancies in the Elderly. Clinics in Geriatric Medicine, 1987, 3, 637-648.	1.0	4
405	Aggressive Therapy for Cancer of the Pancreas. Gastroenterology Clinics of North America, 1990, 19, 935-962.	1.0	15
406	Magnetic nanoparticle hyperthermia for treating locally advanced unresectable and borderline resectable pancreatic cancers: the role of tumor size and eddy-current heating. International Journal of Hyperthermia, 2020, 37, 108-119.	1.1	27
407	Complete Remission of Nonresectable Pancreatic Cancer After Infusional Colloidal Phosphorus-32 Brachytherapy, External Beam Radiation Therapy, and 5-Fluorouracil. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 355-360.	0.6	21
408	Current Issues in Cancer Management of carcinomas of the upper gastrointestinal tract. BMJ: British Medical Journal, 1994, 308, 834-838.	2.4	23
409	Postoperative Gemcitabine Alone and Concurrent with Radiation Therapy in Locally Advanced Pancreatic Carcinoma. Tumori, 2010, 96, 560-567.	0.6	2
410	Proton Therapy and Concomitant Capecitabine for Non-Metastatic Unresectable Pancreatic Adenocarcinoma. International Journal of Particle Therapy, 2014, 1, 692-701.	0.9	38
411	Pancreatic Cancer: Local Success and Distant Failure. Oncologist, 1998, 3, 178-188.	1.9	17
412	Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. Journal of Gastrointestinal Oncology, 2018, 9, 922-935.	0.6	4
413	Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy. World Journal of Gastroenterology, 2008, 14, 7183.	1.4	19

#	Article	IF	CITATIONS
414	Combined radiochemotherapy in patients with locally advanced pancreatic cancer: A meta-analysis. World Journal of Gastroenterology, 2013, 19, 7461.	1.4	43
415	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 7275.	1.4	26
416	Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer. Radiation Oncology Journal, 2018, 36, 200-209.	0.7	10
417	The role of radiotherapy in management of pancreatic cancer. Journal of Gastrointestinal Oncology, 2011, 2, 157-67.	0.6	31
418	Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. Journal of Gastrointestinal Oncology, 2012, 3, 326-34.	0.6	44
419	A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer. Journal of Gastrointestinal Oncology, 2013, 4, 123-30.	0.6	16
420	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. Cancer Research and Treatment, 2016, 48, 1045-1055.	1.3	10
421	Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 598.	2.3	63
422	Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6573-6578.	0.5	10
423	Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 5168.	1.7	1
424	Pankreastumoren. , 2000, , 735-754.		0
425	Erkrankungen von Leber, Gallenwegen und Pankreas. , 2003, , 863-954.		0
426	Palliative Strahlentherapie. , 2004, , 435-444.		0
427	Assessment and strategy of treatment for inoperable pancreatic cancer. Suizo, 2005, 20, 349-356.	0.1	5
428	Malignome des Gastrointestinaltrakts. , 2007, , 573-690.		0
429	Stereotactic Radiosurgery for Unresectable Adenocarcinoma of the Pancreas: Initial Experience at Sinai Hospital of Baltimore. , 2007, , 241-246.		0
430	Postoperative sequence chemoradiotherapy for advanced gastric cancer: an analysis of 36 cases. World Chinese Journal of Digestology, 2007, 15, 3856.	0.0	1
431	Treatment strategy for locally advanced pancreatic cancer. Suizo, 2007, 22, 36-42.	0.1	0

		CITATION RE	PORT	
#	Article		IF	Citations
432	The Evolution of Chemoradiation Strategies for Locally Advanced Pancreatic Cancer. , 20	008, , 497-510.		0
433	Neoadjuvant Treatment for Resectable and Locally Advanced Pancreatic Cancer. , 2008,	, 549-562.		0
434	Comparing Concurrent Chemoradiotherapy to Chemotherapy Alone for Locally Advanced Unresectable Pancreatic Cancer. The Journal of the Korean Society for Therapeutic Radio Oncology, 2009, 27, 64.	d logy and	0.1	1
435	Chemotherapy and Radiotherapy in Pancreatic Cancer. , 2009, , 481-500.			0
436	The Results of Radiotherapy in Locally Advanced, Unresectable Pancreatic Cancer. The Jo Korean Society for Therapeutic Radiology and Oncology, 2009, 27, 145.	urnal of the	0.1	0
437	Chemotherapie beim Pankreaskarzinom. , 2010, , 380-385.			0
438	Cancer of the Pancreas. , 2010, , 801-819.			0
439	Strahlentherapie in der Behandlung des Pankreaskarzinoms. , 2010, , 437-443.			0
440	Cancer of the Stomach. , 2010, , 788-800.			0
441	Developments in Chemoradiation for Advanced Pancreatic Cancer. , 2010, , 951-970.			0
442	Unresectable Pancreatic Cancer. , 2011, , 205-224.			0
443	Combined Modality Therapy in Cancer Management. , 2011, , 483-517.			0
444	Chimiothérapie et radiothérapie des cancers pancréatiques. , 2011, , 415-424.			0
446	Literaturhinweise und Internetadressen. , 2012, , e1-e61.			0
447	Malignome des Gastrointestinaltrakts. , 2012, , 557-665.			0
448	A Matter of Timing: Is There a Role for Radiation in Locally Advanced Pancreatic Cancer, a When?. American Society of Clinical Oncology Educational Book / ASCO American Socie Oncology Meeting, 2012, , 238-242.	and If So, ty of Clinical	1.8	1
450	Chemoradiotherapy versus chemotherapy in patients with locally advanced pancreatic casingle center study. Suizo, 2013, 28, 42-48.	ancer -a large	0.1	1
451	Therapiekonzepte. , 1987, , 1-899.			1

#	Article	IF	Citations
452	Medical Management of Gastrointestinal Cancer. Medical Radiology, 1990, , 247-277.	0.0	0
453	Strahlentherapie des Magen-Karzinoms. , 1992, , 148-157.		0
454	CHEMOTHERAPY IN THE MANAGEMENT OF MALIGNANT GASTROINTESTINAL DISEASE. Gastroenterology Clinics of North America, 1992, 21, 695-714.	1.0	0
455	Pankreaskarzinom. , 1993, , 205-213.		0
456	Pankreaskarzinom. , 1998, , 621-638.		0
457	Malignome des Gastrointestinaltrakts. , 2015, , 579-693.		0
458	Treatment of abdominal tumors using radiotherapy. Revista Da Associação Médica Brasileira, 2015, 61, 108-113.	0.3	1
459	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2016, , 1-27.		0
460	Impact of jaw position on sparing organs at risk in 3-dimensional conformal radiation therapy of pancreatic cancer. International Journal of Cancer Therapy and Oncology, 2016, 4, 4117.	0.2	1
461	Chemotherapy in the Management of Pancreatic Cancer. , 2017, , 387-419.		0
462	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 1-27.		0
463	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 1-27.		0
464	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 749-775.		0
466	Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries. Pancreas, 2021, 50, 1230-1235.	0.5	0
467	The role of radiation for pancreatic adenocarcinoma. Journal of Pancreatology, 2020, 3, 72-80.	0.3	6
468	Radiation Sensitizers, Fractionation Schedules, and Future Clinical Trials. , 2002, , 301-310.		0
472	Unresectable Locally Advanced Pancreatic Cancer: Concurrent Chemotherapy. , 2008, , 227-236.		0
473	Management of Locally Advanced and Recurrent Pancreas Cancer. , 2008, , 689-694.		0

ARTICLE IF CITATIONS Pankreaskarzinom., 0,, 713-733. 0 474 Neoplasien des Pankreas und der Gallenwege., 2007, , 976-984. 476 The role of radiation therapy in pancreas cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, 20-8. 0.8 25 Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm 479 phase II study. Nagoya Journal of Medical Science, 2019, 81, 233-239 Borderline Resectable and Locally Advanced Pancreatic Cancers. Pancreas, 2021, 50, 1243-1249. 480 0.5 3 Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical Tumor Volume for Pancreatic Ductal Adenocarcinoma of the Head: The "Triangle Volume†Practical Radiation Oncology, 2022, 12, 215-225. 1.1 Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally 483 0.7 12 Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. Annals of Surgical Oncology, 2022, 29, 2456-2468. High local failure rates despite high marginâ€negative resection rates in a cohort of borderline 484 resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation 1.3 therapy following multiâ€agent chemotherapy. Cancer Medicine, 2022, , . Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced 485 3 1.7 Pancreatic Cancer: A Propensity Score-Matched Analysis. Cancers, 2022, 14, 1166. Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pancreatic cancer. Clinical Journal of 0.4 Gastroenterology, 2022, 15, 635-641. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. Practical Radiation 487 1.1 5 Oncology, 2022, 12, 511-523. Emerging drugs in pancreatic cancer. Expert Opinion on Emerging Drugs, 2004, 9, 73-89. 1.0 Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?. 491 1.1 3 Life, 2022, 12, 465. Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP: 492 1.5 Journál of the Pancreas, 2013, 14, 337-9. 494 Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer., 2022, , 891-917. 0 A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer. Journal of Gastrointestinal Oncology, 2022, 13, 1989-1996. 496 Management of Resectable and Borderline Resectable Disease: Radiation Oncology., 2022, 153-171. 0 Management of Locally Advanced/Metastatic Disease: Radiation Oncology., 2022, , 107-124.

<u></u>		<b>D</b>	_
	ON	NEDC	ND T
CITATI		<b>NLPU</b>	VIC I

#	Article	IF	CITATIONS
499	Clinical Outcomes of Intraoperative Radiotherapy, Postoperative Radiotherapy, and Definitive Radiotherapy for Non-metastatic Pancreatic Cancer. Kurume Medical Journal, 2022, , .	0.0	0
500	The Current Role of Radiation in Pancreatic Cancer and Future Directions. Clinical Colorectal Cancer, 2023, , .	1.0	1
501	Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis. BMC Gastroenterology, 2023, 23, .	0.8	0
502	Radioterapia: papel actual en el cáncer de páncreas. latreia, 2012, 25, 149-158.	0.1	Ο
503	Survival Outcomes and Failure Patterns in Patients with Inoperable Non-Metastatic Pancreatic Cancer Treated with Definitive Radiotherapy. Cancers, 2023, 15, 2213.	1.7	0